MicroRNAs (miRNAs) are small RNAs of 19-25 nucleotides that are negative regulators of gene expression. To determine whether miRNAs are associated with cytogenetic abnormalities and clinical features in acute myeloid leukemia (AML), we evaluated the miRNA expression of CD34+ cells and 122 untreated adult AML cases using a microarray platform. After background subtraction and normalization using a set of housekeeping genes, data were analyzed using Significance Analysis of Microarrays. An independent set of 60 untreated AML patients was used to validate the outcome signatures using real time PCR. We identified several miRNAs differentially expressed between CD34+ normal cells and the AML samples. MiRNA expression was also closely associated with selected cytogenetic and molecular abnormalities like t(11q23), isolated 
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Introduction
Acute myeloid leukemia (AML) is a cytogenetically and molecularly heterogeneous disorder characterized by differentiation arrest and malignant proliferation of clonal myeloid precursors. 1 Patients with intermediate and poor risk cytogenetics represent the majority of AML; chemotherapy based regimens fail to cure most of these patients and stem cell transplantation is frequently the treatment of choice. [2] [3] Since allogeneic stem cell transplantation is not an option for many patients with high risk leukemia for a variety of reasons, there is a critical need to improve our understanding of the biology of these leukemias to develop novel therapies.
MicroRNAs (miRNAs) are non-coding RNAs of 19-25 nucleotides in length that regulate gene expression by inducing translational inhibition and cleavage of their target mRNAs through base pairing to partially or fully complementary sites. 4 MiRNAs are involved in critical biological processes, including development, cell differentiation, stress response, apoptosis and proliferation. 4 Recently, miRNA expression has been linked to hematopoiesis and cancer. [5] [6] [7] [8] [9] [10] [11] In mice, the ectopic expression of miR-181 in hematopoietic progenitor cells led to proliferation in the B-cell compartment. 5 Likewise, important roles for miRNAs have been found during human granulocytic, erythrocytic and megakaryocytic differentiation. [6] [7] [8] The first report linking miRNAs and cancer involved chronic lymphocytic leukemia (CLL). 9 A cluster of two miRNAs, miR-15a and miR-16-1, was found to be located in the minimal region of deletion (~30 kb) at 13q14, and to be deleted or down regulated in ~60% of CLL samples. 9 Further studies confirmed the widespread involvement of miRNAs in cancer. [10] [11] Little is know however about miRNA expression in AML. Here, we analyzed a large set of AML patients with Table 1 ]. A second cohort of 54 AML patients with relapsed (n=34) or refractory (n=20) disease obtained from the MDACC was used to sought differences in the miRNA expression between newly diagnosed and relapsed/primary refractory AML patients (Table S7) . Informed consent was obtained from the patients to procure and bank the cells for future research according to institutional guidelines. Patient's samples were prepared by Ficoll-Hypaque (Nygaard) gradient centrifugation, enriched for leukemic cells by CD3/CD19 depletion (MACS, Miltenyi Biotech) and cryopreserved. 12 Cytogenetic analyses of the samples were performed at diagnosis or at relapse, using unstimulated short-term (24-, 48-, and 72-hour) cultures with or without a direct method and G-banding. The criteria used to describe a cytogenetic clone and description of karyotype followed the recommendations of the International System for Human Cytogenetic Nomenclature. 13 At least 20 bone selected erythrocyte precursors from four healthy donors were purchased from Allcells (Emeryville, CA). Bone marrow CD34+ progenitors from 10 healthy donors were purchased from Allcells. In vitro differentiated megakaryocytes were obtained as previously described.
8
RNA extraction and miRNA microarray experiments. RNA extraction and miRNA microchip experiments were performed as previously described. 15 The miRNA microarray is based on a one-channel system. 15 The chips contain gene-specific oligonucleotide probes, spotted by contacting technologies and covalently attached to a Survival analysis and definitions. Overall survival was calculated from the time of diagnosis until the date of death (censoring for alive patients at the time of the last follow-up); and event-free survival (EFS) from the time of diagnosis until relapse or death (censoring for patients who were alive at the time of the last follow up). In the first cohort of 122 AML patients, we used the SAM method, which involved a modified Cox proportional-hazards maximum-likelihood score, to identify a set of miRNAs whose expression significantly correlated with the duration of survival. Next we validated these miRNAs in an independent cohort of 60 newly diagnosed AML patients ( Table 1 ) by using qRT-PCR. Univariate Cox proportional hazard method was used in this validation set of 60 patients to identify miRNAs associated with OS and EFS. Multivariate proportional-hazards analysis was then used to asses whether miRNAs could predict outcome independently from other factors (e.g. cytogenetics and FLT-ITD+) using the R 2.4.0 software. To select best among all the multivariate models we used the Akaike Information Criteria (AIC). Kaplan-Meier (KM) plots were used to display the association of miRNA with outcome. To generate the KM plots, miRNA levels, measured by qRT-PCR, were converted into discrete variables by splitting the samples into two classes (high and low expression, according to the median expression in the full set of samples). Survival curves were obtained for each group and compared by using the log-rank test.
Statistical Analysis. Fisher's exact test, t-test and chi-square were used to compare baseline characteristics and average miRNA expression between groups of patients. All
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for windows).

Results
AML patients reveal a distinct spectrum of miRNA expression in comparison to
normal CD34+ progenitor cells.
We compared 122 newly diagnosed AML samples (Table 1 ) with CD34+ cells from 10 normal donors for differential miRNA expression using a previously described and validated miRNA microarray platform. 15 We identified 26 down-regulated miRNAs and none up-regulated in AML samples compared with CD34+ normal cells ( Table 2) . To validate these results we performed qRT-PCR for 7 of the down-regulated miRNAs (miR-
126, miR-130a, miR-135, miR-93, miR-146, miR-106b and miR-125a
) using a subset of randomly chosen AML samples and 4 CD34+ samples obtained from different donors.
As shown in Figures 1A and B, we confirmed the down-regulation of the above miRNAs in AML samples with respect to the bone marrow CD34+ progenitors, except for miR-
135.
Additionally, to validate the results of the microarray platform we performed qRT-PCR for 42 miRNAs whose expression was high, intermediate and low on the chip in 12 randomly chosen AML samples. As shown in Figure S1 , the miRNA levels measured by the microarray and those measured by qRT-PCR highly correlated (r= 0.92, P<0.001), thereby validating the microarray platform as analytical tool to measure miRNA expression.
A subset of miRNAs is associated with specific hematopoietic lineages
For personal use only. significantly down-regulated in mature and precursor hematopoietic cells ( Figure 1C ).
MiRNA-181a is down-regulated in AML with multilineage dysplasia (MLD)
AML with MLD occurs most frequently in older patients and is often associated with unfavorable cytogenetic profile and response to therapy. 19 To investigate whether this group has a characteristic miRNA profile, we compared untreated AML patients with "de novo" or primary AML (n=79) with respect to AML patients with MLD (n=29) as defined by the WHO classification of AML. 19 Using SAM we identified only the downregulation of miR-181a in AML with MLD (FDR 0%, FC >2, SAM scores of -1.68).
Then we compared untreated "de novo" samples (n=79) to untreated patients with therapy related AML (n=12) and identified three up-regulated miRNAs in therapy-related AML patients (miR-190, miR-9 and miR-188, all with FDR of 0%, FC >1.8 and SAM score of >1.8). We did not detect any significant difference of miRNA expression between AML with MLD and therapy-related AML.
MiRNAs correlate positively to white blood cell and blast counts
We investigated whether miRNAs are associated with pretreatment patient characteristics (Table S3) . We validated the microarray results for selected miRNAs (chosen by higher SAM scores) using patient samples from the outcome validation signature cohort (non t(11q23) n=10
and t(9;11) n=3 by qRT-PCR ( Figure S2) . Among the miRNAs down-regulated in balanced 11q23 translocation patients, many are tumor suppressor miRNAs that target Table S6 ]. This signature was not predictive of NK-AML, likely due to the molecular heterogeneity of this subgroup (data not shown). We validated the microarray results for selected miRNAs using patient samples from the outcome validation signature cohort (NK-AML n=12 and abnormal karyotype AML n=22 by qRT-PCR ( Figure S3 ).
MiR-155 is over-expressed in FLT3-ITD mutations in AML patients
To identify miRNAs associated with the presence of 
MicroRNA expression in relapsed and primary refractory AML patients
By using our miRNA platform, we further investigated miRNA profiles of 54 patients with relapsed (n=34) or primary refractory AML (n=20) ( Table S7 ). This independent cohort of treated patient samples was obtained from patients different from the initial 122 cohort. No major differences between untreated (n=122) and treated patients (n=54) were detectable (data not shown). Using this set of 54 treated patients, we analyzed miRNA expression among the different cytogenetics and molecular subgroups (e.g. AML with t(11q23) vs. other karyotypes, FLT3-ITD+ Vs FLT3-wt, etc) using SAM. Similar
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MicroRNAs associated with the outcome
We investigated survival and miRNA expression in 122 newly diagnosed AML patients.
Here, we identified a small number of miRNAs with a FDR lower than 1% and a SAM survival score (Cox regression) higher than 2. All the identified genes, miR-199a, miR- (Figures 3A and B) and EFS (miR-199a P=0.002 and miR-191 P=0.02, log rank-test).
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Discussion
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In this study we used a microarray platform to perform genome wide miRNome analysis of AML samples and normal progenitor CD34+ cells. Most miRNAs were downregulated in AML patients with respect to CD34+ cells. Two recent studies have suggested widespread miRNA down-regulation during in vitro differentiation of CD34+ cells to several lineages. 8, 33 Our data confirmed that the most down-regulated miRNAs in AML with respect to CD34+ cells were also down-regulated in healthy precursors and mature peripheral blood myeloid cells suggesting that a subset of miRNAs in leukemia follow closely the differentiation patterns of miRNA expression in normal hematopoiesis.
Here, we identified molecular signatures associated with several cytogenetic groups. The two strongest signatures were those associated with balanced 11q23 translocations and isolated trisomy 8. The down-regulation of miR-196, known to regulate HOX genes 26 , in patients harboring 11q23 translocations suggests a novel mechanism to explain the upregulation of several HOX genes in these patients. Using the microarray platform we were also able to distinguish between t(6;11) and t(9;11). Among the up-regulated miRNAs in t(6;11), miR-21 has been found over-expressed in many solid tumors. 10 Another study indicated that miR-21 targets PTEN 27 , an important tumor suppressor, and antisense inhibition of miR-21 induces apoptosis of tumor cells "in vitro" and suppresses tumor growth in a xenograft mouse model. 34 Aberrant expression of oncomiRs like miR-21 and miR-26 in t(6;11) may explain the worse prognosis of this subgroup of patients. 31 In contrast, miR-29 family members, down-modulated in balanced 11q23 translocations target the oncogene TCL1 24 and MCL1 23 , a critical apoptosis regulator found up-regulated in cells that are resistant to a variety of chemotherapeutic agents. 35 Moreover other miR-29 family members are down-regulated in high risk CLL 36 and lung cancer.
Interestingly, miR-155 was found to be up-regulated in AML patients with high white count and FLT3-ITD mutations. This miRNA has been recently described to block "in vitro" human myeloid colony formation 38 , halt megakaryopoiesis 38 and induce B-cell lymphoma and leukemia in mice. 39 In this study, there were few patients with favorable cytogenetics, such as inv (16)[4] and t(15;17) [4] . We were not able to identify any characteristic miRNA signature in these two groups of AML patients. The lack of correlation may be due to heterogeneity within the groups and/or to the small sample size.
Although this study was not designed to answer whether miRNAs could predict outcome,
here we describe a miRNA signature significantly associated with overall and event-free survival (OS). A number of observations strengthen our results. First, we identified miRNAs associated with survival despite the overall poor prognosis and short survival of the patients studied here, where outcome differences could be difficult to demonstrate.
Second, high expression of miR-199a and miR-191 were also identified in patients with isolated trisomy 8, a subgroup of AML, which is associated with poor outcome. 31 Third, the outcome signature is constituted of up-regulated miRNAs in common with the shared signatures of six solid tumors (such as miR -20, miR-25, miR-199a and miR-191) . 10 Further studies will be required to address the accuracy and independent prognostic significance of these miRNAs in predicting outcome.
In summary, our study demonstrates that a subset of miRNAs is clearly deregulated in AML and associated with cytogenetic groups and outcome. (30) No statistically significant differences were observed between the two set of patients (microarrays vs. qRT-PCR) by t-test and chi-square, except for the category of AML without maturation (chi-square P=0.03). All the values represent frequencies followed by the percentages. For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From 
